Jade Biosciences, Inc. Payments of Stock Issuance Costs
Jade Biosciences, Inc. (JBIO) reported Payments of Stock Issuance Costs of $307.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-04-25
- Jade Biosciences, Inc. payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- Jade Biosciences, Inc. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. payments of stock issuance costs for the quarter ending 2024-06-30 was $74.00K.
- Jade Biosciences, Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $233.00K.
- Jade Biosciences, Inc. payments of stock issuance costs for fiscal 2024 was $307.00K, a 31.20% increase from fiscal 2023.
- Jade Biosciences, Inc. payments of stock issuance costs for fiscal 2023 was $234.00K, a 36.93% decline from fiscal 2022.
- Jade Biosciences, Inc. payments of stock issuance costs for fiscal 2022 was $371.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $74.00K derived: sum of 3 quarters · filed 2025-03-27 | $307.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $74.00K derived: sum of 2 quarters · filed 2024-11-12 | $307.00K 10-Q · filed 2024-11-12 | $307.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $307.00K 10-Q · filed 2024-08-12 | $307.00K derived: sum of 3 quarters · filed 2025-04-25 | $382.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $233.00K 10-Q · filed 2025-04-25 | $233.00K derived: sum of 2 quarters · filed 2025-04-25 | $308.00K derived: sum of 3 quarters · filed 2025-04-25 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $75.00K derived: sum of 2 quarters · filed 2025-03-27 | $234.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $234.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $159.00K 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $371.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $135.00K 10-Q · filed 2023-11-13 | |||
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.11M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |